U.S. Pharmaceuticals & Biotech High ROE Growth Engines

Incyte

Market Cap: US$23.0b

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Exelixis

Market Cap: US$14.0b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

ACADIA Pharmaceuticals

Market Cap: US$4.4b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Theravance Biopharma

Market Cap: US$877.5m

A biopharmaceutical company, develops and commercializes medicines in the United States.

CorMedix

Market Cap: US$660.6m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Abeona Therapeutics

Market Cap: US$415.5m

A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.

Elite Pharmaceuticals

Market Cap: US$403.8m

A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.

Compugen

Market Cap: US$223.2m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

Oramed Pharmaceuticals

Market Cap: US$166.2m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Vaxart

Market Cap: US$127.9m

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.

Spero Therapeutics

Market Cap: US$98.4m

A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.